Company: ACHV
Filing Date: 2025-03-11
Form Type: 10-K
Source: 0000950170-25-036831
Chunk: 134

Company: ACHIEVE LIFE SCIENCES, INC.
Filing Date: 2025-03-11
Form: 10-K
Item: Item 8
Chunk 134
---
 17,734

    20,819

    Commitments and contingencies [note 12]

    Stockholders' equity:

    Series A convertible preferred stock, $0.001 par value, 9,158 shares designated, zero issued and outstanding at December 31, 2024 and December 31, 2023.

    —

    —

    Series B convertible preferred stock, $0.001 par value, 6,256 shares designated, zero issued and outstanding at December 31, 2024 and December 31, 2023.

    —

    —

    Common stock, $0.001 par value, 150,000,000 shares authorized, 34,685,072and 21,165,760 issued and outstanding at December 31, 2024 and December 31, 2023, respectively.

    103

    90

    Additional paid-in capital

    226,343

    164,209

    Accumulated deficit

    (205,578
    )

    (165,751
    )

    Accumulated other comprehensive income

    31

    4

    Total stockholders' equity

    20,899

    (1,448
    )

    Total liabilities and stockholders' equity
     
    $
    38,633

    $
    19,371

    Going concern [note 1]

See accompanying notes.

68

Achieve Life Sciences, Inc. 

Consolidated Statements of Loss and Comprehensive Loss 

(In thousands, except per share and share amounts) 

    Year Ended December 31,

    2024

    2023

    2022

    EXPENSES

    Research and development
     
    $
    22,817

    $
    15,814

    $
    30,078

    General and administrative

    16,252

    11,436

    10,722

    Total operating expenses

    39,069

    27,250

    40,800

    OTHER INCOME (EXPENSE)

    Interest income

    2,356

    825

    199

    Interest expense [note 9]

    (2,180
    )

    (2,853
    )

    (1,789
    )

    Change in fair value of contingent consideration [note 6